home / stock / morf / morf articles
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher by around 30 points on Monday. The Dow traded down 0.0...
Since Friday, Morphic Therapeutic (NASDAQ: MORF) shares have plunged from $47.92 to $26.25 after the company announced the publication of...
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with ...
Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enhanced backtracking search algorithm to boost the...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, CA / ACCESSWIRE / June 17, 2024 / Johnson Fistel, is investigating potential securities claims against Morphic Holding, Inc. (NASDAQ:MORF) on behalf of stockholders. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws. If yo...
WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will take part in a fireside c...
-α4β7 Inhibition Rapidly Increases the Rolling Velocity and Flux of B Cells in Gut-associated Lymphoid Tissues- -Impact of Potent and Selective Small Molecule Inhibitor Comparable to Monoclonal Antibody Activity- -Preclinical Findings Presented at Digestive Disease...